Indications
Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).
Composition
- Active substance
- odevixibat sesquihydrate
- International name (INN)
- odevixibat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kayfanda
- Active substance
- odevixibat sesquihydrate
- ATC code
- A05AX05
- Therapeutic area
- Pruritus, Alagille Syndrome
- Marketing authorisation holder
- Ipsen Pharma
- Status